Bloomage Biotechnology's sweeping transformation may still be underway. Recently, social media users reported that "Runxiquan REHYADRO, a skincare brand under Bloomage Biotechnology, has closed its Tmall flagship store." When contacted for verification, Bloomage Biotechnology had not responded by press time.
Investigation reveals that the Runxiquan flagship store can no longer be found on Taobao and Tmall platforms. The brand's flagship stores and mini-stores on Douyin and WeChat have also been cleared, with no products currently available for sale. Additionally, the brand's social media updates across various platforms have been dormant for an extended period.
**Tmall Flagship Store Unavailable, Douyin/WeChat Stores Cleared**
Public records show Runxiquan was established in 2019, with its trademark owned by Beijing Huaxi Haiyu Technology Co., Ltd., a 100% subsidiary of Bloomage Biotechnology. The brand positioned itself as a collagen-focused skincare line emphasizing anti-aging and repair benefits.
Runxiquan previously operated official flagship stores on Tmall, Douyin, and WeChat platforms, offering products across multiple categories including single-use capsules, toners, lotions, creams, and face masks.
In an October 2024 media interview, then-brand manager Zhao Yuting stated that the brand's core ingredient was "anti-aging collagen," a combination of type III collagen, elastin, and fibronectin designed to "supplement, lock in, and regenerate collagen." Zhao also mentioned that Runxiquan operated laboratories in France, Japan, and South Korea, with cumulative revenue reaching 300 million yuan from 2020 to October 2024. She expressed ambitions to "target 1 billion yuan."
However, early this month, social media users reported that "Runxiquan's Taobao store has closed." Current searches for "Runxiquan" on Tmall and Taobao yield only three stores named "Runxiquan," "Runxiquan Skincare Store," and "Runxiquan Brand Skincare Store," none of which are official flagship stores.
Social media posts confirm users previously purchased products from the official "Runxiquan Flagship Store" on Tmall. Both the Douyin flagship store and official WeChat mini-store have been completely cleared of inventory.
When asked about clearing product links, Runxiquan's Douyin flagship store customer service cited "internal business adjustments" with no other notifications available. WeChat mini-store customer service claimed ignorance of the situation, stating the store stopped selling products "last month."
The brand's official accounts on Douyin, WeChat, and Xiaohongshu have also ceased marketing activities. The most recent video on the Douyin official flagship store account was posted March 10, featuring promotional content for Runxiquan's hydrating makeup primer. The Douyin account currently has 180,000 followers with 425,000 sales recorded.
The official WeChat mini-store shows it has been operating for 2 years and 348 days, indicating it opened in September 2022 and ran for approximately three years. The last video on Runxiquan's official WeChat video account was posted February 26, 2024, featuring brand ambassador Xue Jianing in the brand's first concept film.
This timeline reveals that Runxiquan's WeChat account stopped operating early last year, while the Douyin account continued until March this year.
Both the Douyin flagship store and WeChat mini-store were operated by Beijing Huaxi Hengmei Trading Co., Ltd., a 100% subsidiary of Beijing Huaxi Haiyu Technology Co., Ltd., making it a subsidiary of Bloomage Biotechnology.
On Xiaohongshu, Runxiquan's official account has 13,000 followers. The account's last activity was April 22, World Earth Day, when Runxiquan partnered with intimate apparel brands IMIS and HUXI on a "Heal the Earth Plan" sustainability initiative. No updates have appeared since.
Currently, Runxiquan products remain available in Bloomage Biotechnology's official WeChat mini-program store, alongside products from Runbaiyuan, Jihuo, and Mibeier brands.
Bloomage Biotechnology had not responded to inquiries about the store closures and future plans by press time.
**Founder Previously Criticized Collagen in Skincare**
Notably, while Runxiquan's products feature combination collagen as their main ingredient, multiple media reports indicate that in April 2023, Bloomage Biotechnology founder Zhao Yan publicly stated at the company's earnings conference that "using collagen in skincare products is just a concept. It cannot be absorbed and doesn't form a protective film on your skin."
Zhao Yan also questioned collagen's applications in medical aesthetics and food, arguing that "no company in the market can produce true human-like collagen, its skin-filling effects in medical aesthetic procedures are quite limited, and much research on collagen lacks scientific basis."
However, Bloomage Biotechnology has repeatedly mentioned "collagen" in annual reports, covering both cosmetic applications and collagen food products. In the company's 2025 interim report released last month, "collagen" appeared 20 times, including references to recombinant type III humanized collagen in raw materials business, hyaluronic acid-collagen composite gels, and collagen dressings.
The financial report shows that in the first half of this year, the company launched six new bioactive raw material products, including BloomColla® Recombinant Type III Humanized Collagen (COL3-INJ01).
Industry veterans suggest that Runxiquan's operational "anomalies" may not stem from Bloomage Biotechnology's lack of confidence in the collagen market, but rather from challenges facing the company's cosmetics-related businesses.
In recent years, Bloomage Biotechnology's four major functional skincare brands—Runbaiyuan, Kwadra, Jihuo, and Mibeier—have experienced significant performance declines. Financial reports show that in the first half of 2025, the company's dermatological science innovation and transformation business (formerly functional skincare business) generated revenue of 912 million yuan, down 33.97% year-over-year. Previously, Runbaiyuan and Kwadra alone each achieved annual revenues exceeding 1.3 billion yuan.
In 2024, all four major brands under Bloomage Biotechnology experienced notable declines: Runbaiyuan generated 923 million yuan (down 22.63%), Kwadra 649 million yuan (down 41.69%), Mibeier 290 million yuan (down 31.76%), and BM Jihuo 279 million yuan (down 52.06%).
Given this context, the closure and inventory clearing of Runxiquan, which was not a core brand, becomes less surprising.
**Increased Focus on Pharmaceutical and Medical Aesthetics**
Beyond the declining dermatological science business, Bloomage Biotechnology recorded its "worst interim results" in the first half of this year across overall performance. The company reported revenue of 2.261 billion yuan, down 19.57% from 2.811 billion yuan in the previous year; net profit attributable to shareholders of 221 million yuan, down 35.38%; and adjusted net profit of 173 million yuan, down 45%.
To reverse this declining trend, Bloomage Biotechnology is seeking new growth drivers, including the pharmaceutical sector. Yesterday (September 8), Sirnaomics announced plans to issue approximately 17.35 million new shares at HK$12 per share (approximately RMB 10.97) to four subscribers including Bloomage Biotechnology (Hong Kong) Limited, representing 14.16% of expanded share capital and raising approximately HK$206 million (RMB 188 million) for general working capital.
Bloomage Biotechnology will subscribe for HK$138 million (approximately RMB 126 million) worth of shares through its wholly-owned subsidiary Bloomage Biotechnology (Hong Kong) Limited, representing a 9.44% stake.
Sirnaomics, established in 2007 and listed on the Hong Kong Stock Exchange in 2021, focuses on developing new drugs based on RNA interference (RNAi) technology and is known as "China's first nucleic acid drug stock." However, the company has remained unprofitable since listing and has not generated any product sales revenue as of June 30 this year.
According to Sirnaomics' 2025 interim report, the company currently has a research pipeline including 14 products and 15 projects. It also has two core RNAi pipelines in clinical stages, demonstrating certain technical potential and clinical value.
Sirnaomics has also made moves in medical aesthetics. Last August, it partnered with medical healthcare investment company Gore Range Capital to establish Sagesse Bio, bringing its RNAi therapeutic products to the aesthetic medicine market.
This investment marks Bloomage Biotechnology's first foray into small nucleic acid and RNAi technology, attracting significant market attention. Industry observers believe that with first-half performance under pressure, Bloomage Biotechnology needs to find new growth curves and further expand its presence in cutting-edge life science fields.
Since last year, Bloomage Biotechnology has been undergoing transformation, designating 2024 as its "transformation year" with particular focus on reforming its dermatological science innovation and transformation business. The company has comprehensively reviewed and adjusted five key areas: operations, products, channels, organization, and branding.
According to public reports, in March this year, Zhao Yan returned to frontline operations and implemented a series of reforms, including announcing decisive "anti-corruption" policies, requiring Bloomage Biotechnology to return to its startup mentality, and reassigning senior management. The 2025 interim report shows that 11 directors, supervisors, and senior management personnel have departed.
These changes indicate that Bloomage Biotechnology remains in a state of dynamic transformation. How the company will continue forward and reverse its performance decline after this period of transformation remains to be seen over time.
Comments